Beam Therapeutics (BEAM) Net Income towards Common Stockholders (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$94.3 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$94.3 million, up 12.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$65.0 million (up 83.17% YoY), and the FY2025 annual result was -$80.0 million, up 78.77% from the prior year.
• Net Income towards Common Stockholders declined to -$94.3 million in Q1 2026 per BEAM's latest filing, from $244.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $244.3 million in Q4 2025 and troughed at -$112.7 million in Q3 2025.
• A 5-year average of -$57.2 million and a median of -$94.3 million in 2026 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders tumbled 289.7% in 2022, then jumped 472.36% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$38.3 million in 2022, then jumped by 472.36% to $142.8 million in 2023, then plunged by 163.27% to -$90.4 million in 2024, then surged by 370.38% to $244.3 million in 2025, then slumped by 138.61% to -$94.3 million in 2026.
• Business Quant data shows BEAM's Net Income towards Common Stockholders at -$94.3 million in Q1 2026, $244.3 million in Q4 2025, and -$112.7 million in Q3 2025.